靶向药物治疗弥漫大B细胞淋巴瘤研究进展  

Progress of targeted drugs for treatment of diffuse large B-cell lymphoma

作　　者：吴家金 平凌燕 朱军[1] 宋玉琴[1] Wu Jiajin;Ping Lingyan;Zhu Jun;Song Yuqin(Department of Lymphoma,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《白血病．淋巴瘤》2023年第3期143-146,共4页Journal of Leukemia & Lymphoma

摘　　要：弥漫大B细胞淋巴瘤(DLBCL)是侵袭性淋巴瘤中最常见的亚型,复发难治DLBCL患者预后较差,临床尚缺少有效的标准治疗方案。如何对复发难治DLBCL患者进行有效治疗一直是研究的热点,目前的新药/技术研究包括双特异性抗体治疗、嵌合抗原受体T细胞(CAR-T)疗法、抗体偶联药物(ADC)治疗等。文章就第64届美国血液学会(ASH)年会关于DLBCL的靶向药物/细胞治疗进展进行综述。Diffuse large B-cell lymphoma(DLBCL)is the most common subtype of aggressive lymphoma.The relapsed/refractory DLBCL patients have poor outcomes and DLBCL is still lack of effective treatment standard regimens.How to effectively treat relapsed/refractory DLBCL patients has become a research hotspot,and the current treatment methods include bispecific antibody therapy,chimeric antigen receptor T-cell(CAR-T)therapy,antibody-drug conjugates(ADC)therapy.This paper reviews the progress of targeted drugs/cell treatment for DLBCL at the 64th American Society of Hematology annual meeting.

关 键 词：淋巴瘤 大B细胞 弥漫性 治疗 基因靶向 

分 类 号：R733.1[医药卫生—肿瘤]